Mascia Adverse Effects of Anti-EGFR Therapy Genetic Ablation of Epidermal EGFR Reveals the Dynamic Origin of
暂无分享,去创建一个
[1] J. Fischer,et al. Epidermal EGFR Controls Cutaneous Host Defense and Prevents Inflammation , 2013, Science Translational Medicine.
[2] M. Washington,et al. Epidermal growth factor receptor inhibits colitis-associated cancer in mice. , 2012, The Journal of clinical investigation.
[3] M. Gnant,et al. Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. , 2012, Cancer treatment reviews.
[4] Raphael Kopan,et al. The black box illuminated: signals and signaling. , 2012, The Journal of investigative dermatology.
[5] T. Mizoguchi,et al. Tetracyclines Convert the Osteoclastic-Differentiation Pathway of Progenitor Cells To Produce Dendritic Cell-like Cells , 2012, The Journal of Immunology.
[6] L. Gleaves,et al. A Critical Role for Macrophages in Promotion of Urethane-Induced Lung Carcinogenesis , 2011, The Journal of Immunology.
[7] Wei-Li Di,et al. Inflammatory skin and bowel disease linked to ADAM17 deletion. , 2011, The New England journal of medicine.
[8] R. Seethala,et al. Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer. , 2011, Oral oncology.
[9] M. Washington,et al. Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. , 2011, The Journal of clinical investigation.
[10] M. Lacouture,et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities , 2011, Supportive Care in Cancer.
[11] J. Verweij,et al. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. , 2010, European journal of cancer.
[12] M. Steinhoff,et al. Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor-induced pruritus. , 2010, Journal of the American Academy of Dermatology.
[13] Yoon-Koo Kang,et al. Investigation of papulopustular eruptions caused by cetuximab treatment shows altered differentiation markers and increases in inflammatory cytokines , 2010, The British journal of dermatology.
[14] U. Rodeck,et al. Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice. , 2009, Cancer Research.
[15] B. De Moor,et al. Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] E. Van Cutsem,et al. Association of progression‐free survival, overall survival, and patient‐reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy , 2009, Cancer.
[17] D. Threadgill,et al. Generation and validation of mice carrying a conditional allele of the epidermal growth factor receptor , 2009, Genesis.
[18] Andrew Snyder. Is there a silver lining? l , 2008 .
[19] G. Tortora,et al. EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.
[20] Gary Clark,et al. Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies , 2007, Clinical Cancer Research.
[21] M. Lacouture. Mechanisms of cutaneous toxicities to EGFR inhibitors , 2006, Nature Reviews Cancer.
[22] Y. Komiyama,et al. Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib , 2006, Journal of Cancer Research and Clinical Oncology.
[23] J. Segre,et al. Epidermal barrier formation and recovery in skin disorders. , 2006, The Journal of clinical investigation.
[24] K. Nishio,et al. Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib. , 2005, Lung cancer.
[25] R. Perez-soler,et al. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] M. Vidal,et al. A keratin K5Cre transgenic line appropriate for tissue‐specific or generalized cre‐mediated recombination , 2004, Genesis.
[27] E. Wagner,et al. Mice humanised for the EGF receptor display hypomorphic phenotypes in skin, bone and heart , 2003, Development.
[28] G. Girolomoni,et al. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. , 2003, The American journal of pathology.
[29] S. Akira,et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. , 1998, Immunity.
[30] K. Ley,et al. Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[31] T. Magnuson,et al. Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development. , 1997, The American journal of pathology.
[32] O. Smithies,et al. Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[33] A. Ullrich,et al. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. , 1995, The EMBO journal.
[34] K. Herrup,et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. , 1995, Science.
[35] N. Van Rooijen,et al. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. , 1994, Journal of immunological methods.
[36] D. Priebat,et al. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. , 1982, The Journal of investigative dermatology.